These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 27714642)

  • 21. Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives.
    Alexopoulos D; Pappas C; Sfantou D; Lekakis J
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):13-22. PubMed ID: 29228817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging P2Y12 receptor antagonists: role in coronary artery disease.
    Oliphant CS; Doby JB; Blade CL; Das K; Mukherjee D; Das P
    Curr Vasc Pharmacol; 2010 Jan; 8(1):93-101. PubMed ID: 19485932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cangrelor - Expanding therapeutic options in patients with acute coronary syndrome.
    Kubica J; Adamski P; Dobrzycki S; Gajda R; Gąsior M; Gierlotka M; Jaguszewski M; Legutko J; Lesiak M; Navarese EP; Niezgoda P; Ostrowska M; Pawłowski T; Tycińska A; Umińska JM; Witkowski A; Gil R
    Cardiol J; 2024; 31(1):133-146. PubMed ID: 37964649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cangrelor vs. glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention.
    Yerasi C; Case BC; Chezar-Azerrad C; Forrestal BJ; Medranda GA; Shea C; Zhang C; Ben-Dor I; Satler LF; Bernardo NL; Hashim H; Garcia-Garcia HM; Waksman R
    Am Heart J; 2021 Aug; 238():59-65. PubMed ID: 33961829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data.
    Tamborini Permunian E; Riva N; Guasti L; Squizzato A
    Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):625-37. PubMed ID: 25728292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-Analysis of the Role of Cangrelor for Patients Undergoing Percutaneous Coronary Intervention.
    Majmundar M; Kansara T; Jain A; Shah P; Mithawala P; Desai R; Shah P; Doshi R
    Am J Cardiol; 2019 Apr; 123(7):1069-1075. PubMed ID: 30654930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing the Use of Cangrelor in the Real World.
    Qamar A; Bhatt DL
    Am J Cardiovasc Drugs; 2017 Feb; 17(1):5-16. PubMed ID: 27677505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiplatelet Therapy Bridging With Cangrelor in Patients With Coronary Stents: A Case Series.
    Bowman S; Gass J; Weeks P
    Ann Pharmacother; 2019 Feb; 53(2):171-177. PubMed ID: 30132336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro.
    Judge HM; Buckland RJ; Jakubowski JA; Storey RF
    Platelets; 2016; 27(3):191-5. PubMed ID: 26270719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cangrelor: a review on its mechanism of action and clinical development.
    Ferreiro JL; Ueno M; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2009 Oct; 7(10):1195-201. PubMed ID: 19814662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cangrelor: a novel P2Y12 receptor antagonist.
    Norgard NB
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1219-30. PubMed ID: 19604122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
    White HD; Bhatt DL; Gibson CM; Hamm CW; Mahaffey KW; Price MJ; Steg PG; Stone GW; Cortese B; Wilensky M; Deliargyris EN; Liu T; Prats J; Harrington RA
    JACC Cardiovasc Interv; 2015 Mar; 8(3):424-433. PubMed ID: 25703887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction.
    Mohammad MA; Andell P; Koul S; James S; Scherstén F; Götberg M; Erlinge D
    Platelets; 2017 Jun; 28(4):414-416. PubMed ID: 27885888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y
    Droppa M; Vaduganathan M; Venkateswaran RV; Singh A; Szumita PM; Roberts RJ; Qamar A; Hack L; Rath D; Gawaz M; Fuernau G; de Waha-Thiele S; Desch S; Schneider S; Ouarrak T; Jaffer FA; Zeymer U; Thiele H; Bhatt DL; Geisler T
    Resuscitation; 2019 Apr; 137():205-212. PubMed ID: 30790690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis.
    Gan XD; Wei BZ; Fang D; Fang Q; Li KY; Ding SL; Peng S; Wan J
    Curr Med Res Opin; 2015 Dec; 31(12):2313-23. PubMed ID: 26402735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of P2Y
    Spinthakis N; Farag M; Gue YX; Srinivasan M; Wellsted DM; Gorog DA
    Thromb Res; 2019 Jan; 173():102-108. PubMed ID: 30500673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention.
    Sawlani NN; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL
    Circ Cardiovasc Interv; 2017 Jan; 10(1):. PubMed ID: 28039321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists].
    Cattaneo GJ; Podda GM; Cattaneo M
    Recenti Prog Med; 2011 Apr; 102(4):150-5. PubMed ID: 21572491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on the clinical development of cangrelor.
    Ueno M; Ferreiro JL; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2010 Aug; 8(8):1069-77. PubMed ID: 20670184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.